|Bid||53.87 x 1800|
|Ask||53.98 x 4000|
|Day's Range||51.13 - 52.70|
|52 Week Range||38.48 - 61.71|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||15.40|
|Earnings Date||May 02, 2022 - May 06, 2022|
|Forward Dividend & Yield||1.60 (3.21%)|
|Ex-Dividend Date||May 12, 2022|
|1y Target Est||59.33|
Pfizer (PFE) obtains Fast Track designation for its investigational combination therapy - ervogastat and clesacostat for the treatment of NASH.
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
NEW YORK, May 26, 2022--Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizer’s investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis: ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi). Fast Track is a process designed to facilitate the development and ex